ATE471983T1 - Dengue viren, die in mosquitos nicht replizieren, zur verwendung als impfstoff - Google Patents

Dengue viren, die in mosquitos nicht replizieren, zur verwendung als impfstoff

Info

Publication number
ATE471983T1
ATE471983T1 AT99906779T AT99906779T ATE471983T1 AT E471983 T1 ATE471983 T1 AT E471983T1 AT 99906779 T AT99906779 T AT 99906779T AT 99906779 T AT99906779 T AT 99906779T AT E471983 T1 ATE471983 T1 AT E471983T1
Authority
AT
Austria
Prior art keywords
defective
replication
flaviviruses
present
vaccines
Prior art date
Application number
AT99906779T
Other languages
English (en)
Inventor
Lingling Zeng
Lewis Markoff
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE471983T1 publication Critical patent/ATE471983T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99906779T 1998-09-02 1999-02-05 Dengue viren, die in mosquitos nicht replizieren, zur verwendung als impfstoff ATE471983T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9898198P 1998-09-02 1998-09-02
PCT/US1999/002598 WO2000014245A1 (en) 1998-09-02 1999-02-05 Dengue viruses that are replication defective in mosquitos for use as vaccines

Publications (1)

Publication Number Publication Date
ATE471983T1 true ATE471983T1 (de) 2010-07-15

Family

ID=22271837

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99906779T ATE471983T1 (de) 1998-09-02 1999-02-05 Dengue viren, die in mosquitos nicht replizieren, zur verwendung als impfstoff

Country Status (6)

Country Link
EP (1) EP1108036B1 (de)
AT (1) ATE471983T1 (de)
AU (1) AU774045B2 (de)
CA (1) CA2341354C (de)
DE (1) DE69942525D1 (de)
WO (1) WO2000014245A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
JP2005510244A (ja) * 2001-11-26 2005-04-21 ザ・ユニヴァーシティ・オヴ・クイーンズランド フラビウイルスワクチン送達系
US7851194B2 (en) * 2004-06-14 2010-12-14 The United States Of America As Represented By The Department Of Health And Human Services West Nile viruses with mutations in the 3′ terminal stem and loop secondary structure for use as live virus vaccines
WO2006067122A2 (en) 2004-12-20 2006-06-29 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
AU2006245734C1 (en) 2005-05-12 2012-05-24 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
MY151062A (en) 2006-02-27 2014-03-31 Univ Texas Pseudoinfectious flavivirus and uses thereof
CN105246506A (zh) 2013-06-21 2016-01-13 默沙东公司 登革病毒疫苗组合物及其使用方法
BR112017013270A2 (pt) 2014-12-22 2018-03-06 Merck Sharp & Dohme ?composição de vacina contra vírus da dengue, métodos para induzir uma resposta imune contra dengue, para reduzir a probabilidade de infecção por dengue, ou prevenir ou atenuar os sintomas da mesma, e, uso de uma composição de vacina contra vírus da dengue?.
JP6949027B2 (ja) * 2015-12-23 2021-10-20 バルネバ オーストリア ジーエムビーエイチ ジカウイルスワクチン
AU2017222644B2 (en) * 2016-02-25 2021-07-29 The Trustees Of The University Of Pennsylvania Novel vaccines against Zika virus

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233770D1 (de) * 1991-09-19 2009-10-29 Us Health Chimäre und/oder wachstumgehemmte Flaviviren

Also Published As

Publication number Publication date
WO2000014245A1 (en) 2000-03-16
AU2661099A (en) 2000-03-27
AU774045B2 (en) 2004-06-17
DE69942525D1 (de) 2010-08-05
CA2341354C (en) 2009-10-20
EP1108036B1 (de) 2010-06-23
CA2341354A1 (en) 2000-03-16
EP1108036A1 (de) 2001-06-20

Similar Documents

Publication Publication Date Title
ATE471983T1 (de) Dengue viren, die in mosquitos nicht replizieren, zur verwendung als impfstoff
ATE233101T1 (de) Polynukleotide vakzine gegen den papilloma virus
NO20091761L (no) Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav
ATE229978T1 (de) Helicobacter proteine und impstoffe
ATE396739T1 (de) Entwicklung einer vakzine zur prävention von infektionen mit filovirus bei primaten
MY141594A (en) 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
DE69830579D1 (de) Chimäre impfstoffe gegen flaviviren
WO2004045529A3 (en) West nile virus vaccine
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
ATE508635T1 (de) Virusvektoren und ihre verwendung bei therapeutischen methoden
BR0312474A (pt) Partìcula viral adjuvante
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
PT789590E (pt) Imunopotenciacao induzida por quitosano
MY144492A (en) Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types
AU2001290178A1 (en) A hepatitis c virus non-structural ns3/4a fusion gene
MXPA03000061A (es) Manipulacion de virus de arn encadenados negativos mediante redisposicion de sus genes y usos de los mismos.
NO983946D0 (no) Parapoksyviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner
WO2003076591A8 (en) Compositions and methods for generating an immune response
ATE366819T1 (de) Genetische immunisierung gegen zervixkarzinom
LU91151I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétaniqud, d'anatoxine coquelucheuse, d'hémagglutine filamenteuse, de pertactine, d'antigène de surf ace recombinant de virus de l'hépatite B (protéineS), e virus poliomyélitique inactivé type 1, type3et de polyoside d'Haemophilus influenzae type b.
WO2002078631A3 (en) Improved conditionally replicating vectors for inhibiting viral infections
TW200509964A (en) VP1 of foot-and-mouth disease virus
ATE283066T1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
ATE453708T1 (de) Impfstoff gegen west nile virus
PT1149901E (pt) Mutantes de pestivirus e vacinas contendo os mesmos

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties